We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN icon
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMRN icon
1
Amarin Corp
AMRN
$244M
$78M 9.15%
797,196
+264,523
+50% +$25.5M
2018 Q1
11 quarters
UTHR icon
2
United Therapeutics
UTHR
$23.2B
$69.6M 8.17%
458,636
+217,732
+90% +$28.6M
2020 Q2
2 quarters
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$58.8M 6.89%
+376,200
New +$48.3M
2020 Q4
0 quarters
TGTX icon
4
TG Therapeutics
TGTX
$8.57B
$44.9M 5.27%
863,851
-159,479
-16% -$5.39M
2018 Q1
11 quarters
AZN icon
5
AstraZeneca
AZN
$259B
$42.6M 5%
426,216
+395,748
+1,299% +$41.9M
2019 Q4
4 quarters
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$38.8M 4.56%
530,976
-76,781
-13% -$5.71M
2020 Q2
2 quarters
FATE icon
7
Fate Therapeutics
FATE
$231M
$36.3M 4.26%
399,499
-135,537
-25% -$8.42M
2018 Q4
8 quarters
GSK icon
8
GSK
GSK
$98.2B
$35.2M 4.13%
757,265
+705,767
+1,370% +$32.4M
2018 Q1
11 quarters
ASND icon
9
Ascendis Pharma A/S
ASND
$14.9B
$31.2M 3.66%
187,043
+26,039
+16% +$4.31M
2017 Q4
12 quarters
CTLT icon
10
DELISTED
CATALENT, INC.
CTLT
$29.1M 3.41%
279,503
+139,174
+99% +$13.5M
2020 Q3
1 quarter
NVST icon
11
Envista
NVST
$3.77B
$29.1M 3.41%
+861,355
New +$25M
2020 Q4
0 quarters
DHR icon
12
Danaher
DHR
$163B
$28.1M 3.29%
142,500
+107,126
+303% +$21.5M
2018 Q3
9 quarters
TEVA icon
13
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$26.5M 3.11%
2,748,250
+353,895
+15% +$3.39M
2020 Q3
1 quarter
AVTR icon
14
Avantor
AVTR
$10.9B
$25.9M 3.04%
+920,650
New +$23.7M
2020 Q4
0 quarters
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.88B
$23.6M 2.77%
138,644
+136,747
+7,209% +$20.3M
2020 Q2
2 quarters
ELV icon
16
Elevance Health
ELV
$92.9B
$21.1M 2.48%
+65,771
New +$20.2M
2020 Q4
0 quarters
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
$18.2M 2.13%
909,708
+44,467
+5% +$909K
2017 Q4
12 quarters
QGEN icon
18
Qiagen
QGEN
$9.53B
$17.8M 2.09%
317,680
+159,744
+101% +$8.52M
2020 Q2
2 quarters
ENSG icon
19
The Ensign Group
ENSG
$10.4B
$15.2M 1.78%
208,470
-110,393
-35% -$7.32M
2017 Q4
12 quarters
DCPH icon
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.1M 1.65%
246,240
-156,193
-39% -$9.26M
2018 Q4
8 quarters
GSK icon
21
CALL
GSK
GSK
$98.2B
$13M 1.52%
+282,080
New +$13M
2020 Q4
0 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.3M 1.33%
356,235
+179,477
+102% +$4.72M
2020 Q3
1 quarter
TARO icon
23
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$11.2M 1.31%
152,256
+10,367
+7% +$666K
2019 Q4
4 quarters
HSKA
24
DELISTED
Heska Corp
HSKA
$11.1M 1.3%
76,166
-82,606
-52% -$10.3M
2019 Q1
7 quarters
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$10M 1.17%
+2,408,885
New +$9.51M
2020 Q4
0 quarters
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.